892711-75-0

中文名称 4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺

英文名称 CDN 1163

CAS 892711-75-0

分子式 C20H20N2O2

分子量 320.39

MOL 文件 892711-75-0.mol

更新日期 2023/03/20 15:41:25

892711-75-0 结构式

基本信息物理化学性质安全数据图谱信息 4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺价格(试剂级) 常见问题列表

基本信息

中文别名

化合物CDN1163
4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺

英文别名

CDN1163
4-isopropoxy-N-(2-methylquinolin-8-yl)benzamide
N-(2-methylquinolin-8-yl)-4-propan-2-yloxybenzamide
4-(1-Methylethoxy)-N-(2-methyl-8-quinolinyl)benzamide
Benzamide, 4-(1-methylethoxy)-N-(2-methyl-8-quinolinyl)-
Inhibitor,CDN 1163,Calcium Channel,Ca channels,Ca2+ channels,CDN-1163,CDN1163,inhibit

所属类别

生物化工：生化试剂

物理化学性质

熔点87 - 89°C

储存条件2-8°C

溶解度溶于DMSO(>25mg/ml)

形态粉末

颜色白色至米色

稳定性Stable for 1 year as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.

安全数据

危险性符号(GHS) GHS hazard pictograms

GHS07

警示词警告

危险性描述H302-H315-H319-H335

防范说明P261-P305+P351+P338

图谱信息

4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺(892711-75-0)核磁图(¹HNMR)

4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺价格(试剂级)

报价日期	产品编号	产品名称	CAS号	包装	价格
2025/09/19	S6815	4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺 CDN1163	892711-75-0	5mg	970.46元
2025/09/19	S6815	4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺 CDN1163	892711-75-0	25mg	2900.47元
2025/05/22	HY-101455	4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺 CDN1163	892711-75-0	1 mg	350元

常见问题列表

生物活性

CDN1163是一种 sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) 的小分子变构激活剂，可改善 Ca2+ 稳态。

靶点

Target	Value
SERCA ()

体外研究

CDN1163 (5.5-25 mM; 0-8 hours; rat cardiac myocyte cells) treatment reduces high glucose-induced resistin and nuclear NFATc expression and increases the phosphorylation of AMPKα in a time-dependent manner.

Western Blot Analysis

Cell Line:	Rat cardiac myocyte cells (H9c2)
Concentration:	5.5 mM, 25 mM
Incubation Time:	0 hour, 4 hours, 8 hours
Result:	High glucose-induced resistin and nuclear NFATc expression were significantly reduced. The phosphorylation of AMPKα is increased in a time-dependent manner.

体内研究

CDN1163 (50 mg/kg; intraperitoneal injection; for 5 days; male ob/ob mice and lean ob/+ mice) increases SERCA2 Ca ²⁺ -ATPase activity, decreases endoplasmic reticulum (ER) stress-induced cell death in vitro and improves liver Ca ²⁺ transport activity. CDN1163 reduces blood glucose levels and improves metabolic parameters and gluconeogenic gene expression, reverses hepatic steatosis, inhibits ER stress and ER stress-induced apoptosis, and improves mitochondrial efficiency in ob/ob mice in vivo.

Animal Model:	Male 8-10-week old ob/ob mice and lean ob/+ mice
Dosage:	50 mg/kg
Administration:	Intraperitoneal injection; for 5 days
Result:	Markedly lowered fasting blood glucose, improved glucose tolerance, and ameliorated hepatosteatosis but did not alter glucose levels or body weight. Increased expression of uncoupling protein 1 (UCP1) and UCP3 in brown adipose tissue and reduced the hepatic expression of genes involved in gluconeogenesis and lipogenesis, attenuated ER stress response and ER stress-induced apoptosis, and improved mitochondrial biogenesis, possibly through SERCA2-mediated activation of AMP-activated protein kinase pathway.